AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company's Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Instruments & Supplies
- Sub-Industry: Health Care Equipment
- Exchange: NASDAQ
- Symbol: ANGO
- CUSIP: 03475V10
- Previous Close: $16.54
- 50 Day Moving Average: $16.62
- 200 Day Moving Average: $16.64
- 52-Week Range: $36,504,000.00 - $10.44
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 22.05
- P/E Growth: 1.58
- Market Cap: $603.78M
- Outstanding Shares: 36,504,000
- Beta: 1.02
- Net Margins: -7.91%
- Return on Equity: 4.87%
- Return on Assets: 3.49%
Companies Related to AngioDynamics:
- Debt-to-Equity Ratio: 0.21%
- Current Ratio: 2.91%
- Quick Ratio: 1.80%
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
Where is AngioDynamics' stock going? Where will AngioDynamics' stock price be in 2017?
5 equities research analysts have issued 12 month price targets for AngioDynamics' stock. Their predictions range from $12.00 to $19.00. On average, they anticipate AngioDynamics' share price to reach $16.70 in the next twelve months.
When will AngioDynamics announce their earnings?
AngioDynamics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 5th 2017.
What are analysts saying about AngioDynamics stock?
Here are some recent quotes from research analysts about AngioDynamics stock:
According to Zacks Investment Research, "AngioDynamics reported a mixed second quarter of fiscal 2017, wherein adjusted earnings surpassed the Zacks Consensus Estimate while revenues missed the same. Meanwhile, over the last three months, AngioDynamics has outperformed the broader industry in terms of price. The company has also provided positive earnings guidance for fiscal 2017. Notably, the major growth drivers for the company are the Perpheral Vascular, the NanoKnife and BioFlo Midline product lines. Meanwhile, the discontinuity of the Celerity tip location program under its vascular segment might dent operational efficiency over the long haul. A sluggish capital spending environment is adversely affecting AngioDynamics’ top-line growth. AngioDynamics is exposed to a stringent regulatory environment. Regulatory setbacks might dampen approvals for pipeline products, which will in turn hurt overall growth." (1/11/2017)
Cantor Fitzgerald analysts commented, "We remain confident in our above-consensus F2Q17 adjusted EPS estimate. We are modeling revenues of $91.1M, in line with FactSet consensus of $91.1M, but we have a slightly higher margin outlook than the Street, which we believe should support our adjusted EPS estimate of $0.17, slightly above consensus of $0.16." (12/27/2016)
KeyCorp analysts commented, "The initiation of the PIII for ONS-3010 in psoriasis has been delayed slightly to 2016 from 3Q16. The PIII design has been agreed to by FDA and EMA and the interchangeability study design has been discussed with the FDA. The company continues to seek partnerships in the interim to fund its pipeline programs. ONS-3010 Development Stalling: Mgmt plans to initiate the PIII interchangeability trial with first patient enrolled by end of this month/early October w/ initial patient enrollment in EU/Canada and with patient enrollment in U.S. expected to start in early Jan 2017. We note that mgmt stated the FDA and EMA signed off on a PIII trial design and the company basically needs to submit an IND detailing the pre-agreed plan." (9/12/2016)
Who owns AngioDynamics stock?
AngioDynamics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (8.53%), Broadfin Capital LLC (4.03%), FMR LLC (3.12%), Numeric Investors LLC (2.41%), State Street Corp (2.20%) and Systematic Financial Management LP (2.15%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, Charles R Greiner, David F Burgstahler and Stephen A Trowbridge.
Who sold AngioDynamics stock? Who is selling AngioDynamics stock?
AngioDynamics' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Systematic Financial Management LP, Oxford Asset Management, Tudor Investment Corp Et Al, Menta Capital LLC, Renaissance Technologies LLC, Carleon Capital Partners LLC and Teton Advisors Inc.. Company insiders that have sold AngioDynamics stock in the last year include Avista Capital Partners Gp, Ll, Charles R Greiner, David F Burgstahler and Stephen A Trowbridge.
Who bought AngioDynamics stock? Who is buying AngioDynamics stock?
AngioDynamics' stock was purchased by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Partners Group Holding AG, Russell Investments Group Ltd., Bogle Investment Management L P DE, State Street Corp, Two Sigma Investments LP, Thrivent Financial for Lutherans and Martingale Asset Management L P.
How do I buy AngioDynamics stock?
Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of AngioDynamics stock cost?
One share of AngioDynamics stock can currently be purchased for approximately $16.54.